川田 一郎

Medicine & Life Sciences

1. (R,E)-N-(7-chloro-1-(1-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-1H-benzo(d)imidazol-2-yl)-2-methylisonicotinamide 12%
2. 1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno(3,2-d)pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one 10%
3. Adrenal Cortex Hormones 9%
4. AEE 788 10%
5. Afatinib 23%
6. Anaplastic Lymphoma Kinase 15%
7. Annular Erythema 9%
8. ARQ 197 10%
9. benralizumab 10%
10. Bruton type agammaglobulinemia 8%
11. Caregivers 9%
12. Cell Line 14%
13. ceritinib 8%
14. Cetuximab 13%
15. CH5424802 11%
16. Crizotinib 10%
17. Drug Therapy 9%
18. edoxaban 8%
19. Elderly 11%
20. Epigenomics 8%
21. ErbB Receptors 32%
22. Erlotinib Hydrochloride 9%
23. Esophageal Neoplasms 11%
24. Exons 13%
25. favipiravir 10%
26. Histone-Lysine N-Methyltransferase 9%
27. Insertional Mutagenesis 11%
28. Interstitial Lung Diseases 9%
29. Irinotecan 13%
30. Japan 9%
31. Lung 17%
32. Lung Neoplasms 76%
33. Malignant Mesothelioma 14%
34. Methylation 9%
35. Multicenter Studies 9%
36. Mutation 37%
37. N-(3-fluoro-4-((1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5 yl)oxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide 12%
38. naquotinib 12%
39. navitoclax 9%
40. Neoplasms 19%
41. Nivolumab 15%
42. Non-Small Cell Lung Carcinoma 100%
43. osimertinib 37%
44. Pneumonia 9%
45. Protein-Tyrosine Kinases 41%
46. Receptor Protein-Tyrosine Kinases 15%
47. rice bran saccharide 9%
48. S 1 (combination) 18%
49. Safety 8%
50. Therapeutics 21%